Sign In
Buy NKTX
$2.72
-0.190 (-6.53%)
At Close: Jun 03, 2026
Nkarta to Participate in a September Investor Conference
08:01am, Tuesday, 02'nd Sep 2025
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today
Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights
04:01pm, Tuesday, 12'th Aug 2025
SOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today r
Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series
08:01am, Wednesday, 23'rd Jul 2025
SOUTH SAN FRANCISCO, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today a
Nkarta: Holding Its Support Steady Ahead Of First Data Readouts In 2025
12:40am, Tuesday, 22'nd Jul 2025
Nkarta shares have remained flat since my last review in March, reflecting a wait-and-see market stance. Pipeline updates show steady progress, but no major catalysts have emerged; data readouts are e
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus
08:52am, Friday, 06'th Jun 2025
SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat
Nkarta (NKTX) Moves to Buy: Rationale Behind the Upgrade
01:06pm, Monday, 19'th May 2025
Nkarta (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space
03:46pm, Thursday, 15'th May 2025
Nkarta Inc. NKTX on Wednesday reported a first-quarter loss of 43 cents per share, beating the consensus loss of 44 cents.
Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights
04:01pm, Wednesday, 14'th May 2025
Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded
Nkarta (NKTX) Upgraded to Buy: Here's Why
01:00pm, Monday, 14'th Apr 2025
Nkarta (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Nkarta to Participate in an April Investor Conference
08:01am, Tuesday, 01'st Apr 2025
SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its p
Nkarta: Grinding Lower, Trying To Find Support
10:41am, Monday, 31'st Mar 2025
Nkarta, Inc. has provided significant pipeline updates, showcasing promising advancements in their innovative cell therapy treatments. A financial overview highlights a robust balance sheet, with suff
Nkarta: Betting On The Turnaround
10:15am, Monday, 31'st Mar 2025
Nkarta's NKX019 shows promise in treating autoimmune diseases, despite a 70% stock drop; strategic restructuring extends financial runway to 2029. Q4 and full-year 2024 earnings reveal significant R&D
Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday?
12:50pm, Thursday, 27'th Mar 2025
Nkarta, Inc. NKTX reported a fourth-quarter earnings report on Wednesday with a loss of 35 cents per share, beating the consensus of a loss of 41 cents.
Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
04:01pm, Wednesday, 26'th Mar 2025
Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseases Initial data for NKX019 in multiple autoim
Nkarta (NKTX) Loses -33.62% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:35am, Thursday, 20'th Mar 2025
The heavy selling pressure might have exhausted for Nkarta (NKTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in
